1. |
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - What is it and what can it tell us. N Engl J Med, 2016, 375(23): 2293-2297.
|
2. |
Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA, 2018, 320(9): 867-868.
|
3. |
Makady A, Ham RT, de Boer A, et al. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health, 2017, 20(4): 520-532.
|
4. |
Makady A, van Veelen A, Jonsson P, et al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics, 2018, 36(3): 359-368.
|
5. |
聂晓璐, 王胜锋, 姚晨, 等. 国内外真实世界数据/证据的相关药械监管政策法规及指导原则比较研究. 药物流行病学杂志, 2022, 31(1): 5-12, 49.
|
6. |
Li G, Liu Y, Xie C, et al. Characteristics of expedited programmes for cancer drug approval in China. Nature Rev Drug Dis, 2021, 20(6): 416-416.
|
7. |
国家医疗保障局, 国家卫生健康委. 关于适应国家医保谈判常态化持续做好谈判药品落地工作的通知. 2021.
|
8. |
Bullement A, Podkonjak T, Robinson MJ, et al. Real-world evidence use in assessments of cancer drugs by NICE. Inter J Tech Assess Health Care, 2020, 36(4): 388-394.
|
9. |
Lou J, Kc S, Toh KY, et al. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. Inter J Tech Assess Health Care, 2020, 36(5): 474-480.
|
10. |
Oyebode O, Garrett Z, George E, et al. Evidence requirements for reimbursement of pharmaceuticals across europe. Inter J Tech Assess Health Care, 2015, 31(1-2): 59-67.
|
11. |
Use of real-world evidence in single-drug assessments. 2018.
|
12. |
Procedure and guidelines for CADTH CDR. 2020.
|
13. |
Therapeutic Goods Administration. Real world evidence and patient reported outcomes in the regulatory context. 2021.
|
14. |
NICE. NICE real-world evidence framework. 2022.
|
15. |
CADTH. Developing a Canadian real-world evidence action plan across the drug life cycle. 2020.
|
16. |
IQWIG. Development of scientific concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to 35a social code book V – rapid report. 2019.
|
17. |
HAS. Real-world studies for the assessment of medicinal products and medical devices. 2021.
|
18. |
Hampson G, Towse A, Dreitlein WB, et al. Real-world evidence for coverage decisions: opportunities and challenges. J Compara Effect Res, 2018, 7(12): 1133-1143.
|
19. |
Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Therap Innov Reg Sci, 2018, 52(3): 362-368.
|
20. |
FDA. Use of Real-world evidence to support regulatory decision-making for medical devices. 2017.
|
21. |
FDA. Use of electronic health record data in clinical investigations guidance for industry. 2018.
|
22. |
FDA. Framework for FDA’s real-world evidence program. 2018.
|
23. |
FDA. Submitting documents using real-world data and real-world evidence to FDA for drug and biological products. 2022.
|
24. |
Hines PA, Janssens R, Gonzalez-Quevedo R, et al. A future for regulatory science in the European Union: the European Medicines Agency’s strategy. Nat Rev Drug Discov, 2020, 19(5): 293-294.
|
25. |
EMA. Guideline on registry-based studies. 2021.
|
26. |
PMDA. Basic principles on utilization of registry for applications. 2021.
|
27. |
PMDA. Points to consider for ensuring the reliability in utilization of registry data for applications. 2021.
|
28. |
国家药监局. 关于发布真实世界证据支持药物研发与审评的指导原则(试行)的通告. 2020.
|
29. |
国家药监局. 关于发布真实世界数据用于医疗器械临床评价技术指导原则(试行)的通告. 2020.
|
30. |
ISPOR. Optimizing managed access: lessons from the cancer drugs fund. 2023.
|
31. |
Jade-Xoan P. Authorisation for early access to medicinal products: HAS assessment doctrine. 2021.
|
32. |
Zeitler E, Gilstrap L, Coylewright M, et al. Coverage with evidence development: where are we now? 2022.
|
33. |
Cathy K. US outcomes-based contracts: big uptick in interest, but not execution. 2016.
|
34. |
Chan K, Nam S, Evans B, et al. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian real-world evidence for value of cancer drugs (CanREValue) collaboration. BMJ open, 2020, 10(1): e032884.
|
35. |
Curtis LH, Sola-Morales O, Heidt J, et al. Regulatory and HTA considerations for development of real-world data derived external controls. Clin Pharm Therap, 2023, 114(2): 303-315.
|
36. |
Wang W, Tan J, Wu J, et al. Use of real world data to improve drug coverage decisions in China. BMJ, 2023, 381: e068911.
|
37. |
U. S. FDA. Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products. 2021.
|